A first-in-human phase I clinical trial investigating the safety and efficacy of repeat dosing MSCTRAIL cell therapy in addition to chemotherapy and immunotherapy in patients with advanced lung cancer

Key Points

• Advanced lung cancer patients underwent a trial with MSCTRAIL cell therapy alongside standard treatments, aiming for improved outcomes.
• The safety profile was assessed, ensuring that combined therapy did not lead to unexpected adverse events in this vulnerable group.
• Investigative cell therapy was delivered alongside chemotherapy and immunotherapy, exploring synergistic benefits in treating advanced stages.
• Findings highlight potential advancements in lung cancer treatment strategies, implying broader applicability requiring further validation.